The North America Stem Cell Umbilical Cord Blood Market is estimated to witness a rise in revenue from US$ 1,757.60 Mn in 2022 to US$ 7,051.96 Mn by 2031, at a CAGR of 16.5% during the forecast period 2023–2031.
Stem cell therapy is gaining popularity as a promising alternative to traditional healthcare regimens, especially for the treatment of genetic diseases such as Severe Combined Immune Deficiency (SCID) and aplastic anaemia. Cord blood has emerged as a valuable source of blood stem cells that can help repopulate a patient's blood and immune system. Allogeneic hematopoietic cell transplantation (HCT) therapy is increasingly being used for the treatment of hematologic malignancies, marrow failure, and immune system disorders.
The North America stem cell umbilical cord blood market is witnessing significant growth, driven by the increasing demand for genetic testing, fertility and reproduction-assisted services, and rising spending capacity. The prevalence of genetic diseases such as autoimmune diseases, cancer, and diabetes is also contributing to the demand for genetic testing. The availability of suitable payment plans and significant public investment in stem cell research is further boosting market growth. In addition, the adoption of artificial intelligence and data science is providing expansion opportunities for market players.
However, cord blood stem cell research is not without its ethical and legal challenges, particularly related to the use of embryos. Identifying and labeling cord blood units also poses legal and ethical issues in the marketplace.
To capitalize on the growing demand for stem cell therapies, market players should focus on addressing these challenges through responsible research practices and ethical guidelines. Conducting market research to understand the evolving consumer preferences and regulatory landscape will also be critical to success in this market.
To Get more Insights, Request A Free Sample
Chronic diseases such as cancer, diabetes, and cardiovascular diseases are on the rise in North America. According to the World Health Organization (WHO), chronic diseases account for approximately 80% of all deaths in the region. The increasing prevalence of chronic diseases has led to a growing demand for innovative and effective treatment options such as stem cell therapy. Stem cell therapy offers a promising treatment option for chronic diseases as it can help regenerate damaged tissues and organs, reduce inflammation, and promote tissue healing.
Furthermore, the aging population in North America is also contributing to the increasing prevalence of chronic diseases. As the population ages, the incidence of chronic diseases such as Alzheimer's and Parkinson's disease also increases. This has created a significant demand for stem cell therapy, as it offers a potential cure for these diseases. The rising demand for stem cell therapy is expected to drive the growth of the stem cell umbilical cord blood market in North America.
Governments in North America have been supporting stem cell research and development through various initiatives and funding programs. For instance, the National Institutes of Health (NIH) in the U.S. has been providing funding for stem cell research since the early 2000s. In addition, the Canadian government has been supporting stem cell research through the Stem Cell Network, a network of researchers and industry partners that promotes the development of stem cell therapies.
Moreover, governments in North America have been revising their regulations to facilitate stem cell research and development. For instance, the U.S. Food and Drug Administration (FDA) has issued guidelines for the use of stem cells in clinical trials, while Health Canada has established regulations for the use of stem cells in medical treatments. These initiatives and regulatory reforms have encouraged the growth of the stem cell umbilical cord blood market in North America.
The government support for stem cell research has also attracted significant private investment in the sector. Venture capital firms and biotechnology companies have been investing heavily in stem cell research and development, which is expected to further boost the growth of the stem cell umbilical cord blood market in North America.
Despite the significant potential of stem cell therapy, ethical and legal challenges continue to hamper its growth in North America. The use of embryonic stem cells for research purposes is a contentious issue, with some groups opposing it on ethical grounds. In addition, the labeling and identification of cord blood units pose significant legal and ethical challenges in the marketplace.
Furthermore, there is a lack of uniform regulations across North America regarding the use of stem cells for medical treatments. The regulatory environment for stem cell therapy is complex and varies across different jurisdictions, which can create uncertainty for market players. These challenges can result in delays in the approval of new stem cell therapies, which can negatively impact the growth of the stem cell umbilical cord blood market in North America.
The ethical and legal challenges associated with stem cell therapy highlight the need for responsible research practices and ethical guidelines. Market players need to work closely with regulatory authorities to ensure that their stem cell therapies comply with existing regulations and ethical guidelines. Failure to do so can lead to negative publicity and potential legal action, which can damage the reputation and growth prospects of market players.
The stem cell therapy market is segmented based on therapeutics, with the immune disorders segment expected to grow at the highest CAGR during the forecast period. This is due to the high prevalence of inherited immune system disorders in North America. Immune disorders are a broad category of diseases that result from the immune system attacking healthy cells in the body. Some examples of immune disorders that can be treated with stem cell therapy include Severe Combined Immune Deficiency (SCID), Wiskott-Aldrich Syndrome, and Chronic Granulomatous Disease (CGD). Stem cell therapy offers a promising treatment option for these disorders, as it can help rebuild a patient's immune system with healthy cells.
The diabetes segment holds the highest share in the North America stem cell umbilical cord blood market in 2022. Diabetes is a chronic disease that affects millions of people worldwide. Researchers have been exploring the use of umbilical cord blood for the treatment of diabetes, as it contains stem cells that can differentiate into insulin-producing cells. The potential of stem cell therapy for diabetes has generated significant interest and investment in the market. The increasing research activities in this area are expected to drive the growth of the diabetes segment in the stem cell therapy market.
The stem cell therapy market is also segmented based on application, with regenerative medicine holding the significant share in the market in 2022. Regenerative medicine involves the use of stem cells to repair or replace damaged or diseased tissues and organs in the body. Stem cell therapy offers several benefits in regenerative medicine, including the potential to regenerate damaged tissues and organs, reduce inflammation, and promote tissue healing. The increasing prevalence of chronic diseases, coupled with the growing demand for personalized medicine, is expected to drive the growth of the regenerative medicine segment in the stem cell therapy market.
The hematopoietic stem cell therapy segment is projected to grow at the highest CAGR in the market over the forecast period. Hematopoietic stem cells are responsible for producing all types of blood cells, including red blood cells, white blood cells, and platelets. Hematopoietic stem cell therapy involves the transplantation of these cells to treat various blood disorders, such as leukemia, lymphoma, and myeloma. The increasing incidence of blood disorders, coupled with the rising demand for hematopoietic stem cell therapy, is expected to drive the growth of this segment in the stem cell therapy market.
To Understand More About this Research: Request A Free Sample
The U.S. dominates the stem cell umbilical cord blood market in 2022. The country has a well-established healthcare infrastructure, coupled with the presence of major key players in the market. The U.S. is also home to several leading research institutions and universities that conduct extensive research on stem cell therapy. The increasing prevalence of chronic diseases and the growing demand for personalized medicine are expected to drive the growth of the stem cell therapy market in the U.S.
On the other hand, Mexico is anticipated to project the highest CAGR in the North America market during the forecast period. The country has been witnessing a rising adoption of stem cell umbilical cord blood services due to the increasing prevalence of chronic diseases and the growing demand for regenerative medicine. The government of Mexico has also been taking initiatives to promote stem cell research and development, which is expected to further boost the growth of the stem cell therapy market in the country.
Furthermore, the rising investments by government and private organizations in stem cell research and development in Mexico are expected to drive market growth in the coming years. The increasing awareness about the benefits of stem cell therapy and the availability of affordable treatment options are also expected to contribute to the growth of the stem cell umbilical cord blood market in Mexico. The country's large population, coupled with its increasing healthcare expenditure, is expected to provide significant growth opportunities for market players in the coming years.
North America Stem Cell Umbilical Cord Blood Market is segmented based on therapeutics, applications and country.
Stem cell therapy is one of the types of therapies that are being introduced for the betterment and advancement of healthcare sector and people around the world are turning to them and rejecting traditional regimens of drugs and hospital visits.
Stem cell therapy is an expensive therapy as stem cell field is still highly specialized and has not been adopted by the mainstream and insurance companies. Additionally, there are very few sources for stem cells, labs that are equipped to process stem cells and reputable clinics that provide the treatments.
The North America stem cell umbilical cord blood market is studied from 2018-2031.
The different segmentations of the North America stem cell umbilical cord blood market are therapeutics, applications and country.
The adoption of artificial intelligence and data science provides a lucrative growth opportunity in the North America stem cell umbilical cord blood market.
The U.S. held the major share in terms of revenue, in the North America stem cell umbilical cord blood market in 2022.
The growth rate of the North America stem cell umbilical cord blood market is 16.5%, with an estimated value of US$ 7,051.96 Million by 2031.
Factors such as increasing demand of genetic testing, fertility and reproduction assisted services and rise in spending capacity and suitable payment plans drives the growth in the North America stem cell umbilical cord blood market during forecast period.
Legal and ethical issues during collections is a restraining factor which inhibits the growth of the market during the forecast period.
The immune disorders segment is anticipated to grow at the highest CAGR during the forecast period owing to high prevalence of inherited immune system disorders in North America.
Cord blood has huge potential to treat chronic diseases such as cancer, diabetes, blood and immune diseases. Also, it has been extensively used for treatment of genetic diseases.
The key players operating in the market include Advanced Cell Technology, Inc., Americord Registry LLC, Athersys, Inc., California Stem Cell (CSC), CBR Systems, Inc., LifeCell International Pvt. Ltd., MEDIPOST, Magenta Therapeutics, Mesoblast Ltd, Cryo-Save, Opexa Therapeutics, Inc., Regrow Biosciences Pvt Ltd., Smart Cells International Ltd., Tacitus Therapeutics, Sino Biological and Teva Pharmaceuticals among others.
LOOKING FOR COMPREHENSIVE MARKET KNOWLEDGE? ENGAGE OUR EXPERT SPECIALISTS.
SPEAK TO AN ANALYST
.png)
Features | Type of License | |||
 Single User |   Multi User |  Corporate | ||
| e-Access | ✓ | ✓ | ✓ | |
User Sharing | 1 User Only | 2-6 Users | Unlimited within Company/Enterprise | |
⨉ | ⨉ | ✓ | ||
Free Customization | Up To 30 hrs work | Up To 60 hrs work | Up To 80 hrs work | |
Deliverable |
| ✓ | ✓ | ✓ |
| ⨉ | ✓ | ✓ | |
| ⨉ | ⨉ | ✓ | |
Analyst Support | 4 Month Post purchase | 7 Month Post purchase | One Year Post purchase | |
Free Report update in next update cycle | ⨉ | ⨉ | ✓ | |
Free Industry Update (Within 180 days) | ⨉ | ⨉ | ✓ | |
Benefit | Up to 20% off on next purchase | Up to 30% off on next purchase | Up to 40% off on next purchase | |
| Report ID: AA0422200 | Delivery: 2 to 4 Hours 
.svg)
